Table 4.
Clinical trial studies of lung cancer therapies using lipid nanoparticles.
| Study Title | Conditions | Status | Assigned Number |
|---|---|---|---|
| Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | Small Cell Lung Cancer | Recruiting | NCT03088813 |
| Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | Small Cell Lung Cancer | Recruiting | NCT04381910 |
| Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study (LIPUSU) | Squamous Non-small-cell Lung Cancer | Active, not recruiting | NCT04381910 |
| Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer | Lung Cancer | Completed | NCT00059605 |
| BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Lung Cancer | Active, not recruiting | NCT00828009 |
| Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer | SCLC and Carcinoma, Small Cell | Completed | NCT00046787 |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | Non-small Cell Lung Cancer | Completed | NCT00960115 |
| Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | Head and Neck Cancer, Lung Cancer, Ovarian Cancer | Completed | NCT00006036 |
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in Advanced NSCLC | Non-small Cell Lung Cancer | Recruiting | NCT03987867 |
| A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | NCT04047251 |
| TUSC2-Nanoparticles and Erlotinib in Stage IV Lung Cancer | Lung Cancer | Active, not recruiting | NCT01455389 |
| Doxil Topotecan, Doublet Cancer Study | Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer | Completed | NCT00252889 |
| TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone | Carcinoma, Non-Small-Cell Lung | Not yet recruiting | NCT04486833 |
| Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-Small Cell Lung Cancer | Leptomeningeal Metastases | Completed | NCT03101579 |
| Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases | Lung Cancer, Metastatic Cancer | Completed | NCT00004930 |
| VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer | Lung Cancer | Terminated | NCT00003847 |
| Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Recurrent Small Cell Lung Carcinoma | Completed | NCT00856037 |
| Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs | Lung Cancer, Malignant Mesothelioma, Metastatic Cancer | Completed | NCT00020124 |
| Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors | Completed | NCT02262455 |
| An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | Brain Metastases, Lung Cancer Breast Cancer | Completed | NCT01386580 |
| Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer | Lung Cancer | Completed | NCT00003364 |
| A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide | Small Cell Lung Carcinoma | Completed | NCT00759824 |
| Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer | Lung Cancer | Completed | NCT00002822 |
Data retrieved from the US National Institutes of Health website (http://clinicaltrials.gov/) on 21 August 2011 [113].